Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant camrelizumab plus chemotherapy in elderly patients with locally advanced esophageal squamous cell carcinoma
ChiCTR2500104016Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, paclitaxel, tegafur in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sun Yat-sen University Cancer Center. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
camrelizumabpaclitaxeltegafur
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500104016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104016.